Amerise Biosciences Ltd
Incorporated in 1984, Amerise Biosciences Ltd specializes in NDA, 505(b)(2), and complex
formulations.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Industrials Capital Goods Industrial Products Plastic Products - Industrial
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Interest Received on Loans Given Rs in lakhs ・Standalone data |
|
||||||
| Number of Equity Investee Companies (Quoted Equity Holdings) count ・Standalone data |
|||||||
| Number of Unquoted Investments (Preference Shares, Warrants and Private Equity) count ・Standalone data |
|||||||
| Profit/(Loss) from Partnership Firm Rs in lakhs ・Standalone data |
|||||||
| Short-Term Capital Gains Rs in lakhs ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting.
- Board meeting on 30 Oct 2026 to approve Q2 and half-year unaudited financial results.
-
Updation In The Website Of The Company.
- Company updated its website to www.amerisebiosciencesltd.bar and requested records be amended.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- AGM on 24 Sep 2026 approved FY26 accounts and appointed Albert Hines as Whole-time Director and CFO.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
ABL is an integrated pharmaceutical company specializing in NDA, 505(b)(2), and complex formulations. Its core expertise spans the development of injectables, ophthalmic,
and oral dosage forms, offering end‑to‑
end capabilities from concept to clinic.
The company provides regulatory‑compliant support for 505(b)(2) products and generic filings, including pre‑IND meetings with the
FDA, IND‑enabling studies, product registration, and clinical service management.